Effect of ivabradine on heart rate during MSCT CA

• Research type

  Research Study

• Full title

  Effects of a 10 or 15 mg single intravenous bolus of ivabradine versus placebo on heart rate control during a multislice computed tomography coronary angiography for the evaluation of coronary artery disease. A randomised, double blind, international, multicenter study.

• IRAS ID

  1689

• Sponsor organisation

  International Centre for Therapeutic Research (UK and IRL)

• Eudract number

  2007-006793-28

• ISRCTN Number

  N/A

• Clinicaltrials.gov Identifier

  N/A

• Research summary

  Multi-Slice Computed TomographyCoronary Angiography (MSCT CA) is an imaging technique used to visualise the vessels perfusing the heart muscle. This method allows theevaluation of possible or existing coronary artery disease (CAD). A high heartrate can however impair the quality of the image obtained and medication iscommonly given to lower the heart rate. For certain patients, however, theusual type of heart rate lowering agent cannot be used. Ivabradine, developedby the Institut de Recherche Internationales Servier (I.R.I.S.), is a novelheart rate lowering medication and has already proven its efficacy in the oraltreatment of stable angina. This study is carried out to evaluate the heartrate lowering effect of a single intravenous administration of ivabradineversus placebo during the MSCT CA procedure. Patients necessitating a MSCT CAscan and who have a contra-indication to standardly used heart rate loweringagents, will be recruited from NHS hospital sites across the UK.

• REC name

  London - City & East Research Ethics Committee

• REC reference

  08/H0703/102

• Date of REC Opinion

  12 Nov 2008

• REC opinion

  Further Information Favourable Opinion